Glenmark's Glenn Saldanha seeks a new holy grail as generic drugs run dry
Sixteen years ago, when Glenn Saldanha of Glenmark Pharma took over his father's business he decided that instead of just imitating old drugs, he would also innovate new ones
Glenmark's anti-myeloma drug gets clinical trial nod from USFDA
The US health regulator has cleared Glenmark Pharma's investigational new drug application to initiate phase one study of GBR 1342, a humanised monoclonal antibody for the treatment of multiple... Press Release
Sub:- Glenmark Pharmaceuticals to Initiate Clinical Study for GBR 1342, Second Investigational New Drug from Immuno-Oncology Portfolio With reference to the subject mentioned above, kindly find attached media release which is self-explanatory. Glenmark Pharma hits 52-week low post Q4 results
The stock hit 52-week low of Rs 716, down 5.5%, extending its Friday's 16% on BSE. Glenmark shares plunge 16% on Q4 disappointment
The company reported lower than expected profit, guides for 12-15 sales growth in FY18 Board recommends Dividend
Glenmark Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 11, 2017, inter alia, has recommended Dividend @ 200% i.e. Rs. 2/- per share (face value of Re. 1/- each) on the Equity Share Capital of the Company for the financial year 2016 - 2017 subject to the approval of the Shareholders at the ensuing Annual General Meeting. Outcome Of The Board Meeting - May 11, 2017.
The Board of Directors of Glenmark Pharmaceuticals Limited at its meeting held on May 11, 2017, which commenced at 11.00 a.m. and concluded at 6.45 p.m., considered and approved the following: 1.Audited Financial Results for the year ended March 31, 2017 2.Recommended Dividend @ 200% i.e. Rs. 2/- per share (face value of Re. 1/- each) on the Equity Share Capital of the Company for the financial year 2016 - 2017 3.Re-appointment of Mr. Glenn... Earnings Call Slated For Friday, May 12, 2017 At 8:30 A.M. 9:30 A.M. (IST)
Enclosed please find herewith the details of Earnings Call slated for Friday, May 12, 2017 at 8:30 a.m. 9:30 a.m. (IST), for your information and record. Please note that the recording of the call will be available on our website within 24 hours of the call. Board Meeting May 11, 2017
We have to inform you that, pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations And Disclosures Requirements) Regulations, 2015, a meeting of the Board of Directors will be held on Thursday, May 11, 2017 to consider and approve the Standalone and Consolidated Audited Financial Results of the Company for the year ended March 31, 2017 and to consider and recommend dividend, if any, on Equity Shares for the year ended March 31, 2017.